Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data ...
Elicio Therapeutics, Inc. (ELTX)
Company Research
Source: Yahoo! Finance
7P and preclinical data on the use of intratumoral ELI-004 (AMP-CpG) for solid tumor immunotherapy ELI-002 7P induced mKRAS-specific T cell responses in 99% of evaluable patients (89/90), demonstrating potent and consistent immune activation Robust immune responses were elicited across all seven mKRAS antigens, with 80% response rate to each individual KRAS mutation and 88% of patients generating responses to their own tumor-specific mutation 86.8% (66/76) of patients induced cytotoxic mKRAS-specific T cell responses; 75% (57/76) induced CD8 T cells and 75% (57/76) induced CD4 T cells mKRAS-specific T cell responses were observed across diverse HLA types, supporting the potential applicability of ELI-002 7P across a broad and genetically diverse patient population BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment
Show less
Read more
Impact Snapshot
Event Time:
ELTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ELTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ELTX alerts
High impacting Elicio Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ELTX
News
- Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology OfficerGlobeNewswire
- Elicio Therapeutics: Running On Fumes, But A Definitive Readout Appears Imminent [Seeking Alpha]Seeking Alpha
- Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITCGlobeNewswire
- Elicio Therapeutics to Present Clinical and Preclinical Data at the SITC 2025 Annual MeetingGlobeNewswire
- Elicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P TrialGlobeNewswire
ELTX
Sec Filings
- 12/4/25 - Form EFFECT
- 10/7/25 - Form SCHEDULE
- 9/17/25 - Form 8-K
- ELTX's page on the SEC website